Gt biopharma presented preclinical data demonstrating novel mesothelin-targeted trike® driving cytotoxicity across all stages of non-small cell lung cancer at esmo tat 2022

Brisbane, calif., march 9, 2022 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary tri-specific natural killer (nk) cell engager, trike® protein biologic technology platform, presented preclinical data demonstrating its novel trike driving nk cell immunotherapy against non-small cell lung cancer (nsclc) in the hypoxic solid tumor microenvironment at esmo's targeted anticancer therapies congress (tat).
GTBP Ratings Summary
GTBP Quant Ranking